DISSEMINATED INFECTION WITH VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS (VISA) IN A 37-YEAR-OLD

被引：0
|
作者：
Heller, David [1 ]
Sisson, Stephen [1 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF GENERAL INTERNAL MEDICINE | 2011年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：S471 / S472
页数：2
相关论文
共 50 条
  • [1] Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid
    Balkhair, Abdullah
    Al Muharrmi, Zakariya
    Darwish, Laila
    Farhan, Hatem
    Sallam, Mansour
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E227 - E229
  • [2] Heteroresistance in Vancomycin-Intermediate Staphylococcus aureus (VISA), susceptible or resistant?
    Labarca, Jaime
    REVISTA CHILENA DE INFECTOLOGIA, 2015, 32 (05): : 497 - 498
  • [3] Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
    Su, Michelle
    Davis, Michelle H.
    Peterson, Jessica
    Solis-Lemus, Claudia
    Satola, Sarah W.
    Read, Timothy D.
    PEERJ, 2021, 9
  • [4] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Jung Wan Park
    Hyungmin Lee
    Jung Wook Kim
    Bongyoung Kim
    Scientific Reports, 9
  • [5] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Park, Jung Wan
    Lee, Hyungmin
    Kim, Jung Wook
    Kim, Bongyoung
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    Fong, R. K. C.
    Low, J.
    Koh, T. H.
    Kurup, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (08) : 983 - 987
  • [7] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    R. K. C. Fong
    J. Low
    T. H. Koh
    A. Kurup
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28
  • [8] Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA)
    Howden, BP
    INTERNAL MEDICINE JOURNAL, 2005, 35 : S136 - S140
  • [9] Vancomycin-intermediate resistance in Staphylococcus aureus
    Hiramatsu, Keiichi
    Kayayama, Yuki
    Matsuo, Miki
    Aiba, Yoshifumi
    Saito, Michie
    Hishinuma, Tomomi
    Iwamoto, Akira
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2014, 2 (04) : 213 - 224
  • [10] Vancomycin-intermediate Staphylococcus aureus in Korea
    Kim, MN
    Pai, CH
    Woo, JH
    Ryu, JS
    Hiramatsu, K
    JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) : 3879 - 3881
12345